Across TCGA pan-cancer cohorts, AMZ2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of AMZ2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where AMZ2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types AMZ2 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

HNSC, CCRCC, and PDAC are the cancer types where AMZ2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AMZ2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.307	.001	8	view →
CCRCC	All	All	+0.232	.001	7	view →
PDAC	Female	II,III,IV	+0.515	.001	3	view →
LUAD	Female	III,IV	−0.324	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AMZ2 RNA expression & survival · all AMZ2 data types